SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.13-0.5%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Olu Emuleomo who started this subject3/3/2004 7:11:03 AM
From: Robert K.   of 17367
 
Heads up> there is a pretty big post approval raptiva study going on in psoriasis. One has to wonder whats up with that.
One possibility is to get doctors and patients faster onto the raptiva bandwagon. It could certainly be something else though. Point to always remember is that raptiva is a continued therapy sales should build upon themselves.
I also wonder how long the companies will seek to keep other trials under wraps. I am guessing like everyone else.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News